In this issue of Neuron, Tufail et al. present an underlying mechanism for microglia-mediated elimination of virally transduced cells in the central nervous system. These findings could contribute to the development of improved gene therapies for various neurological disorders by exploring why microglia destroy viable cells following viral infection.
''Bring out your dead! Bring out your dead!'' In a classic scene from the movie Monty Python and the Holy Grail, an irreverent mortician piles mounds of dead bodies onto a wheelbarrow while combing the squalor of a medieval village. When one body objects, ''I'm not dead!'' the mortician bashes him on the head and continues with his morbid duty. Much like this mortician, the garbage collectors of the brain, microglia, sometimes inappropriately clear living cells as if they were dying or dead. In this issue of Neuron, Tufail et al. (2017) explore the reasons why microglia eat viable cells after viral infection in hopes of improving the efficiency of gene delivery to the brain.
In 1999, Jesse Gelsinger died at the age of 18 while enrolled in a clinical trial for genetic correction of ornithine transcarbamylase (OTC) deficiency. Although he harbored a mild form of the disease that was relatively well managed with diet and medication, Gelsinger received the maximum dose of adenovirus, eliciting a massive immune response and multiorgan failure. The tragedy shook the medical community and raised serious questions about clinical trial regulations, informed consent, and the future of gene therapy as a curative solution for various genetic diseases. In the decades since Gelsinger's death, however, gene therapy researchers have made significant strides to avoid similar adverse events and to make viral delivery of curative genetic material a safe and effective treatment.
Two prevailing delivery methods are the adenovirus and the adeno-associated virus (AAV). While both vectors are able to infect non-dividing cells, AAVs hold an advantage over traditional adenoviral vectors such as the one that killed Jesse Gelsinger due to their limited pathogenicity (Table 1 ; Thomas et al., 2003) . These properties are especially important when designing gene therapies for disorders of the central nervous system (CNS) where most cells are quiescent and inflammation can have deleterious consequences on cognition and behavior. The current state of ongoing clinical trials reflects this advantage: adenovirus is the most prevalent vector used in gene therapy clinical trials overall, but an overwhelming majority of neurological gene therapy trials use AAVs. Although decades of engineering have produced a sophisticated array of viral vectors to optimize safe delivery of genetic material, gene therapy in the CNS lags behind its counterparts in other tissues. Currently, only 1.8% of gene therapy clinical trials are indicated for neurological diseases, most of which are in phase one or two (Ginn et al., 2013) . Among the many explanations for this discrepancy is the limited efficiency of gene transfer in the CNS due to the unexplained elimination of virally transduced cells over time. Previous studies have implicated microglia, the brain-resident phagocytes, in this process (Brown and Neher, 2014) . In this issue of Neuron, Tufail et al. (2017) present an underlying mechanism of microglia-mediated elimination of virally transduced cells in the CNS. These findings could contribute to the development of improved gene therapies for various neurological disorders in the future.
Microglia serve as the immune sentinels of the CNS, constantly surveying the brain parenchyma with their ramified processes to detect pathogens, damage, and debris. Upon injury to the CNS, microglia control further damage by phagocytosing dead or dying cells to prevent the release of pro-inflammatory signals from necrotic tissue. In some circumstances, microglia can even eat live neurons that are stressed but viable (Brown and Neher, 2014) . One of the main mechanisms by which microglia recognize putative phagocytic prey is the engagement between phosphatidylserine (PtdSer) on apoptotic or stressed cells and TAM-receptors on microglia (Arandjelovic and Ravichandran, 2015) . PtdSer is a component of the plasma membrane that is normally confined to the inner leaflet by calcium-dependent scramblases and ATP-dependent flippases and translocases. Upon cell injury or stress, PtdSer is externalized and bound by several opsonins and microglial receptors, including the TAM receptors Mertk and Axl. Engagement of PtdSer with TAM receptors leads to a cascade of signaling events culminating in phagocytosis (Figure 1 ; Fourgeaud et al., 2016) . Although this process is beneficial when the prey is likely to elicit a pro-inflammatory immune response if left untouched, microglia can inappropriately phagocytose viable neurons stressed by elevated glutamate, oxidation, or growth factor deprivation. Similarly, adenoviral infection is a stressful insult that can lead to undesired elimination of transduced cells by microglia via unknown mechanisms. Tufail et al. (2017) set out to elucidate this process and identify target mechanisms to modulate the immune response to viral gene delivery in the CNS.
By using an adenovirus to deliver a red fluorescent protein transgene to the brain, the authors find that red transduced cells are progressively cleared over time by microglia. Furthermore, viral delivery leads to microgliosis, wherein microglia proliferate and display reactive markers indicating an inflammatory response. To further elucidate the mechanism of this immune reaction, the authors inject adenovirus into various mutant mice. When innate immune receptors and sensors or pro-inflammatory cytokines are absent in these mice, transduced brain cells avoid microglial phagocytosis. Of note, type I interferon signaling, a canonical anti-viral immune pathway, does not significantly contribute to clearance. Next, the authors asked what signals on transduced cells target them for elimination and what receptors on microglia recognize these signals. Live animal imaging revealed outer leaflet exposure of PtdSer on morphologically intact transduced cells. This finding informed the hypothesis that TAM receptors on microglia recognize this signal on stressed but live cells and mediate phagocytic clearance. Indeed, Mertk single-knockout or Axl and Mertk double-knockout mice demonstrated reduced cell clearance. Thus, microglia seem to mistake stressed cells for dead ones, much like the aforementioned Monty Python mortician.
Having elucidated one pathway of microglia-mediated cell clearance following viral delivery, the authors were motivated to modulate this pathway to protect transduced cells. Specifically, they sought to inhibit PtdSer externalization by inhibiting a calcium-dependent scramblase, PLSCR1. To do this, they package a short hairpin RNA targeting PLSCR1 along with the red fluorescent protein transgene into a single adenoviral vector. Knockdown of this scramblase in transduced cells abrogated the cells' vulnerability to microglial clearance. In addition, microgliosis surrounding the transduction region was reduced.
In order to show that the surviving cells are still functional, the authors assess the electrophysiological properties of transduced cells using a genetically encoded indicator that lights up green when calcium floods into cells. They chose to express this indicator specifically in astrocytes, star-shaped glial cells involved in bloodbrain barrier maintenance and neuronal support, because most transduced cells in this system are astrocytes and these cells exhibit transient calcium potentials in homeostasis. Adenovirus containing nontargeting control shRNA disturbed calcium signaling in transduced astrocytes, whereas adenovirus containing shRNAs targeting PLSCR1 displayed normal electrophysiological properties. Finally, the authors examined the brains of mice 6 months after viral transduction and found that PLSCR1 knockdown conferred long-term viability to transduced cells.
The findings presented by Tufail et al. (2017) breathe new life into the adenovirus as a safe and effective method to deliver genetic material to the CNS in the laboratory and possibly the clinical setting. This vector has largely been supplanted by the less immunogenic AAV. Indeed, the many clinical trials employing adenoviral vectors in CNS gene therapy aim to elicit potent immune responses against brain tumors. By discovering a way to abrogate the clearance of transduced cells, which reduces microgliosis, the authors encourage researchers to take a second look at the adenovirus. Recent advances in gene editing technology will require effective delivery of large, multikilobase constructs to delicate tissues like the brain (Swiech et al., 2014) . Using the strategy employed in this study, researchers might be able to more effectively generate rapid animal models of neurodegenerative disorders by delivering genetic material directly to the CNS via adenovirus. This would save significant time and effort compared to the arduous task of generating conditional transgene or knockout animal models that are fully backcrossed. In the clinical setting, targeting PLSCR1 to modulate the immune response to adenoviral vectors could enable long-term delivery of therapeutic genes to the CNS without adverse cognitive and behavioral effects.
While these findings might resurrect the use of adenovirus in gene therapy and genetic modeling in the brain, a few caveats remain. It will be important to quantitatively assess the clearance of transduced cells after AAV infection in the CNS to determine if adenovirus coupled with PLSCR1 knockdown is better than the current gold standard. The CMV promoter used in this study is notoriously silenced in mammalian cells. Use of a more robust promoter such as EF1-alpha might further improve long-term transgene expression. Another important caveat is that there might be an evolutionary reason for removal of stressed but viable cells, and inhibition of this process could have adverse consequences that arise after time points or in behaviors not tested in this study. On this topic, the authors note that most cells infected by this particular adenoviral serotype are astrocytes. It will be important to follow up this study with a neuron-tropic viral serotype to determine if the same strategy can be used to protect neurons from clearance while sparing their normal circuitry and electrophysiology. Finally, a common obstacle in the field of microglial biology is the inability to confidently distinguish between resident microglia and invading peripheral macrophages, especially in injury models such as viral infection. Recently characterized microglia-specific markers, including Sall1 and Tmem119, might allow the authors to more confidently ascribe transduced cell clearance to microglia (Buttgereit et al., 2016; Bennett et al., 2016) . Notwithstanding these caveats, Tufail et al. (2017) present a compelling mechanism (Thomas et al., 2003) .
of innate immune response to viral infection and a promising strategy to evade this response. Delivery has been one of the most challenging obstacles in the gene therapy field. Tragedies like the death of Jesse Gelsinger continue to loom over clinicians and regulators. The scientific community's quest to minimize deleterious immune responses to viral delivery methods has resurrected the promise of gene therapy. Tufail et al. (2017) focus on the microglial response to viral infection, and they present important mechanisms and strategies that will hopefully advance the goal of treating neurological disorders with gene therapy.
